The US Food and Drug Administration (FDA) has approved Cobenfy, a up-to-date breakthrough drug for schizophrenia that promises to revolutionize treatment with a novel mechanism, the first of its kind in decades. Schizophrenia is a solemn and disabling mental illness that affects the way a person thinks, feels and behaves. Approximately 1% of Americans suffer […]
Research presented at ESMO 2024 reveals modern groups of women with early stage endometrial and cervical cancer who could benefit significantly from adding immunotherapy to current standard treatments. A first-in-human study has shown “promising” anti-tumour activity of a novel antibody-drug conjugate (ADC) targeting the protein claudin 6 in heavily pre-treated patients with ovarian and endometrial […]
